Virender Kumar

1.6k total citations
40 papers, 1.2k citations indexed

About

Virender Kumar is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Virender Kumar has authored 40 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Biology, 10 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Virender Kumar's work include MicroRNA in disease regulation (8 papers), Hedgehog Signaling Pathway Studies (6 papers) and Liver physiology and pathology (6 papers). Virender Kumar is often cited by papers focused on MicroRNA in disease regulation (8 papers), Hedgehog Signaling Pathway Studies (6 papers) and Liver physiology and pathology (6 papers). Virender Kumar collaborates with scholars based in United States, India and Russia. Virender Kumar's co-authors include Ram I. Mahato, Goutam Mondal, Chalet Tan, Donald W. Coulter, Xiaofei Xin, Qiaozhu Su, Neetu Sud, Amit Chaudhary, Jingyi Ma and Jitender Bariwal and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Biomaterials.

In The Last Decade

Virender Kumar

39 papers receiving 1.2k citations

Peers

Virender Kumar

EPIDE

ONCOL

BIOMA

Shiji Fang China

Serena Mancarella Italy

Liteng Lin China

Junnian Zhou China

Yanmin Xu China

Xu He China

Huan Deng China

Qiyun Tang China

Shangzhi Xie China

Qichang Zheng China

Shiji Fang China

Virender Kumar

828 ×1.3

490 ×1.4

94 ×0.4

EPIDE

234 ×1.0

ONCOL

141 ×0.8

BIOMA

Citations per year, relative to Virender Kumar Virender Kumar (= 1×) peers Shiji Fang

Countries citing papers authored by Virender Kumar

Since Specialization

Citations

This map shows the geographic impact of Virender Kumar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Virender Kumar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Virender Kumar more than expected).

Fields of papers citing papers by Virender Kumar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Virender Kumar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Virender Kumar. The network helps show where Virender Kumar may publish in the future.

Co-authorship network of co-authors of Virender Kumar

This figure shows the co-authorship network connecting the top 25 collaborators of Virender Kumar. A scholar is included among the top collaborators of Virender Kumar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Virender Kumar. Virender Kumar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dong, Yuxiang, et al.. (2024). A novel phosphodiesterase inhibitor for the treatment of chronic liver injury and metabolic diseases. Hepatology. 81(4). 1288–1303. 3 indexed citations

Xin, Xiaofei, Yuxiang Dong, Virender Kumar, et al.. (2024). Anti-CLL1 liposome loaded with miR-497-5p and venetoclax as a novel therapeutic strategy in acute myeloid leukemia. Molecular Therapy. 32(11). 4058–4074. 4 indexed citations

Kumar, Virender, Yuxiang Dong, Donald R. Ronning, et al.. (2023). Targeting BRD4 and PI3K signaling pathways for the treatment of medulloblastoma. Journal of Controlled Release. 354. 80–90. 9 indexed citations

Kumar, Virender & Ram I. Mahato. (2023). Natural killer cells for pancreatic cancer immunotherapy: Role of nanoparticles. Cancer Letters. 579. 216462–216462. 3 indexed citations

Kumar, Virender, Xiaofei Xin, Jingyi Ma, et al.. (2023). Anti-miR-96 and Hh pathway inhibitor MDB5 synergistically ameliorate alcohol-associated liver injury in mice. Biomaterials. 295. 122049–122049. 16 indexed citations

Kumar, Virender, et al.. (2022). Recent advances in drug delivery and targeting to the brain. Journal of Controlled Release. 350. 668–687. 70 indexed citations

Kumar, Virender, et al.. (2021). Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma. Biomaterials. 278. 121138–121138. 19 indexed citations

Bhattarai, Rajan Sharma, Virender Kumar, Svetlana Romanova, et al.. (2020). Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer. Journal of Controlled Release. 329. 585–597. 10 indexed citations

Kumar, Virender, Jitender Bariwal, Ajit S. Narang, et al.. (2020). Functional similarity of modified cascade impactor to deposit drug particles on cells. International Journal of Pharmaceutics. 583. 119404–119404. 5 indexed citations

10.

Bariwal, Jitender, Virender Kumar, Hao Chen, et al.. (2019). Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment. Journal of Controlled Release. 309. 231–243. 16 indexed citations

11.

Kumar, Virender, et al.. (2018). Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis. Molecular Therapy. 26(12). 2798–2811. 25 indexed citations

12.

Su, Qiaozhu, Virender Kumar, Neetu Sud, & Ram I. Mahato. (2018). MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis. Advanced Drug Delivery Reviews. 129. 54–63. 106 indexed citations

13.

Kumar, Virender, et al.. (2018). Impact of miRNA-mRNA Profiling and Their Correlation on Medulloblastoma Tumorigenesis. Molecular Therapy — Nucleic Acids. 12. 490–503. 32 indexed citations

14.

Kumar, Virender, et al.. (2017). Challenges and Recent Advances in Medulloblastoma Therapy. Trends in Pharmacological Sciences. 38(12). 1061–1084. 58 indexed citations

15.

Chaudhary, Amit, Yuxiang Dong, Haizhen A. Zhong, et al.. (2017). Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer. Scientific Reports. 7(1). 1665–1665. 33 indexed citations

16.

Gill, Rupinder Kaur, Virender Kumar, Mahendra Bishnoi, et al.. (2016). Design and Green Synthesis of Thieno[2,3-d]pyrimidine Analogues as Potential Antiproliferative Agents. Anti-Cancer Agents in Medicinal Chemistry. 17(5). 701–711. 5 indexed citations

17.

Dutta, Rinku, et al.. (2016). Pharmacokinetics and Biodistribution of GDC-0449 Loaded Micelles in Normal and Liver Fibrotic Mice. Pharmaceutical Research. 34(3). 564–578. 19 indexed citations

18.

Kumar, Virender, Goutam Mondal, Rinku Dutta, & Ram I. Mahato. (2015). Co-delivery of small molecule hedgehog inhibitor and miRNA for treating liver fibrosis. Biomaterials. 76. 144–156. 60 indexed citations

19.

Kumar, Virender & Ram I. Mahato. (2014). Delivery and Targeting of miRNAs for Treating Liver Fibrosis. Pharmaceutical Research. 32(2). 341–361. 44 indexed citations

20.

Chitkara, Deepak, et al.. (2012). miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Letters. 334(2). 211–220. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact